UMIN-CTR History

Name:  UMIN ID:


Unique ID issued by UMIN UMIN000016439
Receipt number R000019091
Scientific Title Phase II Clinical Study Evaluating the Efficacy and Safety of Cetuximab Rechallenge in Patients with Wild-Type RAS, Unresectable, Progressive/Recurrent Colorectal Cancer Refractory to Fluoropyrimidines, Oxaliplatin, Irinotecan, Cetuximab and Bevacizumab: The E-Rechallenge Trial
Date of disclosure of the study information 2015/02/04
Last modified on 2024/01/16 16:23:50

No. Disposal Last modified on Item of update
1 Insert 2015/02/04 14:56:42
2 Update 2015/04/20 15:13:17 Organization
Organization
3 Update 2015/04/23 11:43:04 Name of secondary funder(s)
Name of secondary funder(s)
4 Update 2016/03/08 16:45:31 Last name of lead principal investigator
Last name of lead principal investigator
Organization
Email
Organization
5 Update 2017/01/25 17:20:00 Last follow-up date
6 Update 2017/12/01 16:17:16 Recruitment status
Last follow-up date
7 Update 2017/12/01 16:23:02 Name of primary person or sponsor
Organization
Institutions
8 Update 2019/11/22 13:43:49 Recruitment status
Date of IRB
9 Update 2024/01/16 16:23:50 Recruitment status